《Clinical Cancer Research》于2022年8月31日在线发表了《Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer》研究评价了EndoPredict 在绝经前女性中的评估可靠性 管腔雌激素受体阳性 (ER+)、人表皮生长因子2阴性 (HER2-)乳腺癌(BC)是 BC 中最常诊...
2015年发表在NEJM的TAILORx 研究是一项前瞻性的临床试验,拟验证21基因检测在HR+HER2-LN阴性浸润性乳腺癌患者中的临床价值,即通过21基因表达检测筛选出可避免行辅助化疗的低复发风险乳腺癌患者。该试验入组18~75 岁HR+HER2-腋窝淋巴结阴性浸润性乳腺癌患者原发肿瘤大小1.1~5.0 cm 任何病理学分级,或者0.6~1.0 cm ...
因此为了帮助选择治疗方法,推荐对HR阳性、HER2阴性晚期乳腺癌内分泌治疗±CDK 4/6抑制剂期间复发或进展患者常规进行ESR1突变检测,以尽快筛选出对艾拉司群敏感人群。 参考文献 1. FDA approves elacestrant for ER-positive, HER2-nega...
An abstract is unavailable.StockwellSerena
[2]Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-47. [3]Burstein HJ. Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. N Engl J Med....
Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.
SAJI S, TAIRA N, KITADA M, et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial [J]. Lancet Oncol, 2022, S1470-2045(...
Ibrahim NK, Hamilton EP, Kim S-B, et al. Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study. J Clin ...
[2]Zhang LH, Song GH, Shao B, et al. The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis[J]. Anticancer Drugs, 2022, 33(1):e635-e643. doi: 10.1097/CAD...
2.K. Watanabe, N. Niikura, Y. Kikawa, et al. Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial). Abstract 228P. Annals of Oncology (2022) 33 (suppl_7):...